{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T23:00:02Z","timestamp":1773788402674,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:00:00Z","timestamp":1700697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:00:00Z","timestamp":1700697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s40256-023-00616-2","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T14:02:27Z","timestamp":1700748147000},"page":"71-81","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety and Efficacy of Cangrelor in Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis"],"prefix":"10.1007","volume":"24","author":[{"given":"Mostafa Reda","family":"Mostafa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Magdi","family":"Eid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6647-1866","authenticated-orcid":false,"given":"Ahmed K.","family":"Awad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Takla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul Rhman","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basant E.","family":"Katamesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majd M.","family":"AlBarakat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul Rhman","family":"Ziada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim M.","family":"Al-Azizi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew M.","family":"Goldsweig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,23]]},"reference":[{"issue":"23","key":"616_CR1","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1001\/jama.293.23.2908","volume":"293","author":"SR Mehta","year":"2005","unstructured":"Mehta SR, Cannon CP, Fox KA, Wallentin L, Boden WE, Spacek R, et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA. 2005;293(23):2908\u201317.","journal-title":"JAMA"},{"issue":"23","key":"616_CR2","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1001\/jama.293.23.2935","volume":"293","author":"DL Bhatt","year":"2005","unstructured":"Bhatt DL. To cath or not to cath: that is no longer the question. JAMA. 2005;293(23):2935\u20137.","journal-title":"JAMA"},{"issue":"2","key":"616_CR3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jcin.2011.10.013","volume":"5","author":"EJ Armstrong","year":"2012","unstructured":"Armstrong EJ, Feldman DN, Wang TY, Kaltenbach LA, Yeo K-K, Wong SC, et al. Clinical presentation, management, and outcomes of angiographically documented early, late, and very late stent thrombosis. JACC Cardiovasc Interv. 2012;5(2):131\u201340.","journal-title":"JACC Cardiovasc Interv"},{"issue":"10","key":"616_CR4","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nrcardio.2011.96","volume":"8","author":"O Yousuf","year":"2011","unstructured":"Yousuf O, Bhatt DL. The evolution of antiplatelet therapy in cardiovascular disease. Nat Rev Cardiol. 2011;8(10):547\u201359.","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"616_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nrcardio.2012.199","volume":"10","author":"K Agrawal","year":"2013","unstructured":"Agrawal K, Bhatt DL. Antiplatelet therapy: does prasugrel or ticagrelor suffice in patients with STEMI? Nat Rev Cardiol. 2013;10(3):121\u20132.","journal-title":"Nat Rev Cardiol"},{"issue":"6","key":"616_CR6","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.thromres.2008.01.021","volume":"122","author":"AA Heestermans","year":"2008","unstructured":"Heestermans AA, van Werkum JW, Taubert D, Seesing TH, von Beckerath N, Hackeng CM, et al. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb Res. 2008;122(6):776\u201381.","journal-title":"Thromb Res"},{"issue":"1","key":"616_CR7","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11239-012-0737-3","volume":"34","author":"DJ Angiolillo","year":"2012","unstructured":"Angiolillo DJ, Schneider DJ, Bhatt DL, French WJ, Price MJ, Saucedo JF, et al. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. J Thromb Thrombolysis. 2012;34(1):44\u201355.","journal-title":"J Thromb Thrombolysis"},{"key":"616_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339: b2535.","journal-title":"BMJ"},{"key":"616_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898.","journal-title":"BMJ"},{"issue":"18","key":"616_CR10","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1016\/j.jcin.2016.06.046","volume":"9","author":"J Abtan","year":"2016","unstructured":"Abtan J, Steg PG, Stone GW, Mahaffey KW, Gibson CM, Hamm CW, et al. Efficacy and safety of cangrelor in preventing periprocedural complications in patients with stable angina and acute coronary syndromes undergoing percutaneous coronary intervention: the CHAMPION PHOENIX Trial. JACC Cardiovasc Interv. 2016;9(18):1905\u201313.","journal-title":"JACC Cardiovasc Interv"},{"issue":"3","key":"616_CR11","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1001\/jama.2011.2002","volume":"307","author":"DJ Angiolillo","year":"2012","unstructured":"Angiolillo DJ, Firstenberg MS, Price MJ, Tummala PE, Hutyra M, Welsby IJ, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA. 2012;307(3):265\u201374.","journal-title":"JAMA"},{"issue":"3","key":"616_CR12","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1093\/ehjcvp\/pvz002","volume":"5","author":"P Grimfj\u00e4rd","year":"2019","unstructured":"Grimfj\u00e4rd P, Lagerqvist B, Erlinge D, Varenhorst C, James S. Clinical use of cangrelor: nationwide experience from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J Cardiovasc Pharmacother. 2019;5(3):151\u20137.","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"issue":"24","key":"616_CR13","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","volume":"361","author":"DL Bhatt","year":"2009","unstructured":"Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009;361(24):2330\u201341.","journal-title":"N Engl J Med"},{"issue":"14","key":"616_CR14","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","volume":"368","author":"DL Bhatt","year":"2013","unstructured":"Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013;368(14):1303\u201313.","journal-title":"N Engl J Med"},{"issue":"2","key":"616_CR15","doi-asserted-by":"publisher","first-page":"E60","DOI":"10.1532\/HSF98.20121103","volume":"16","author":"MS Firstenberg","year":"2013","unstructured":"Firstenberg MS, Dyke CM, Angiolillo DJ, Ramaiahm C, Price M, Brtko M, et al. Safety and efficacy of cangrelor, an intravenous, short-acting platelet inhibitor in patients requiring coronary artery bypass surgery. Heart Surg Forum. 2013;16(2):E60\u20139.","journal-title":"Heart Surg Forum"},{"issue":"24","key":"616_CR16","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","volume":"361","author":"RA Harrington","year":"2009","unstructured":"Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009;361(24):2318\u201329.","journal-title":"N Engl J Med"},{"issue":"9909","key":"616_CR17","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1016\/S0140-6736(13)61615-3","volume":"382","author":"PG Steg","year":"2013","unstructured":"Steg PG, Bhatt DL, Hamm CW, Stone GW, Gibson CM, Mahaffey KW, et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet. 2013;382(9909):1981\u201392.","journal-title":"Lancet"},{"issue":"13","key":"616_CR18","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.022125","volume":"10","author":"L De Luca","year":"2021","unstructured":"De Luca L, Steg PG, Bhatt DL, Capodanno D, Angiolillo DJ. Cangrelor: clinical data, contemporary use, and future perspectives. J Am Heart Assoc. 2021;10(13): e022125.","journal-title":"J Am Heart Assoc"},{"issue":"20","key":"616_CR19","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","volume":"33","author":"PG Steg","year":"2012","unstructured":"Steg PG, James SK, Atar D, Badano LP, Bl\u00f6mstrom-Lundqvist C, Borger MA, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569\u2013619.","journal-title":"Eur Heart J"},{"issue":"23","key":"616_CR20","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","volume":"32","author":"CW Hamm","year":"2011","unstructured":"Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the Management of Acute Coronary Syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(23):2999\u20133054.","journal-title":"Eur Heart J"},{"issue":"11","key":"616_CR21","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1056\/NEJMoa1308075","volume":"369","author":"G Montalescot","year":"2013","unstructured":"Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med. 2013;369(11):999\u20131010.","journal-title":"N Engl J Med"},{"issue":"21","key":"616_CR22","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1161\/CIRCULATIONAHA.114.011320","volume":"130","author":"JP Collet","year":"2014","unstructured":"Collet JP, Silvain J, Bellemain-Appaix A, Montalescot G. Pretreatment with P2Y12 inhibitors in non-ST-Segment-elevation acute coronary syndrome: an outdated and harmful strategy. Circulation. 2014;130(21):1904\u201314 (discussion 14).","journal-title":"Circulation"},{"issue":"1","key":"616_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ahj.2015.04.012","volume":"170","author":"D Alexopoulos","year":"2015","unstructured":"Alexopoulos D, Bhatt DL, Hamm CW, Steg PG, Stone GW. Early P2Y12 inhibition in ST-segment elevation myocardial infarction: bridging the gap. Am Heart J. 2015;170(1):3\u201312.","journal-title":"Am Heart J"},{"issue":"11","key":"616_CR24","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045\u201357.","journal-title":"N Engl J Med"},{"issue":"12","key":"616_CR25","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1001\/jama.284.12.1549","volume":"284","author":"DL Bhatt","year":"2000","unstructured":"Bhatt DL, Topol EJ. Current role of platelet glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes. JAMA. 2000;284(12):1549\u201358.","journal-title":"JAMA"},{"issue":"2","key":"616_CR26","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jacc.2016.10.055","volume":"69","author":"M Vaduganathan","year":"2017","unstructured":"Vaduganathan M, Harrington RA, Stone GW, Deliargyris EN, Steg PG, Gibson CM, et al. Cangrelor with and without glycoprotein IIb\/IIIa inhibitors in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol. 2017;69(2):176\u201385.","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"616_CR27","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1001\/jama.2012.50788","volume":"308","author":"A Bellemain-Appaix","year":"2012","unstructured":"Bellemain-Appaix A, O\u2019Connor SA, Silvain J, Cucherat M, Beygui F, Barth\u00e9l\u00e9my O, et al. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. JAMA. 2012;308(23):2507\u201316.","journal-title":"JAMA"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-023-00616-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-023-00616-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-023-00616-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T12:30:09Z","timestamp":1706013009000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-023-00616-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,23]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["616"],"URL":"https:\/\/doi.org\/10.1007\/s40256-023-00616-2","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,23]]},"assertion":[{"value":"4 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AM Goldsweig reports consulting fees from Philips and Inari and speaking fees from Philips and Edwards. MR Mostafa, MM Eid, AK Awad, A Takla, AR Hassan, BE Katamesh, MM AlBarakat, AR Ziada, S Mohamed, and KM Al-Azizi have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No external funding was used in preparation of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"MRM: conceptualization, screening, extraction, writing, and review and editing.\u00a0MME:\u00a0conceptualization and writing\u2014original draft.\u00a0AT: writing\u2014original draft and writing\u2014review and editing.\u00a0AKA: analysis and writing. ARH, BEK, and MMA: literature review, screening, and data extraction. SM and ARZ: data extraction and quality assessment. KMA and AMG: conceptualization, writing, and review and editing.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contribution"}},{"value":"All the data generated or analyzed during this study are included in the published article.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}}]}}